Cristina Popa
@nephroseeker.medsky.social
🩺 Nephrologist = kidney philosopher
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC executive editor
📍@KIreportsbsky.social
📍ERAkidney #ERA25 social media co-leader
#NephSky #MedSky
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC executive editor
📍@KIreportsbsky.social
📍ERAkidney #ERA25 social media co-leader
#NephSky #MedSky
Reposted by Cristina Popa
Apixaban and warfarin being similar is also a red flag
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial - PubMed
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3 …
pubmed.ncbi.nlm.nih.gov
November 26, 2025 at 11:10 PM
Apixaban and warfarin being similar is also a red flag
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
Maybe your nephrologist is a different species? I don't know any nephrologist who'd like to do dialysis when we can avoid it. At least this is how we practice in my part of the world
November 25, 2025 at 6:30 PM
Maybe your nephrologist is a different species? I don't know any nephrologist who'd like to do dialysis when we can avoid it. At least this is how we practice in my part of the world
Don't worry, they will not disappear (they promised 🤞)!
Thank you 😊
Thank you 😊
a black and white image of stitch in the rain with the words please don t leave me
ALT: a black and white image of stitch in the rain with the words please don t leave me
media.tenor.com
November 25, 2025 at 6:16 PM
Don't worry, they will not disappear (they promised 🤞)!
Thank you 😊
Thank you 😊
Thank you for having so much trust in us! 😊
a cartoon of alice from alice in wonderland saying " thank you "
ALT: a cartoon of alice from alice in wonderland saying " thank you "
media.tenor.com
November 25, 2025 at 6:11 PM
Thank you for having so much trust in us! 😊
This is beyond #TopNephrology it's not only shows what nephrologists have been saying for years, but also for all of medicine to know: proteinuria is a marker of both kidney and cardiovascular disease
#Medsky
pubmed.ncbi.nlm.nih.gov/41183334/
#Medsky
pubmed.ncbi.nlm.nih.gov/41183334/
Proteinuria or Albuminuria as Markers of Kidney and Cardiovascular Disease Risk : An Individual Patient-Level Meta-analysis - PubMed
National Kidney Foundation and National Institute of Diabetes and Digestive and Kidney Diseases.
pubmed.ncbi.nlm.nih.gov
November 24, 2025 at 10:55 PM
This is beyond #TopNephrology it's not only shows what nephrologists have been saying for years, but also for all of medicine to know: proteinuria is a marker of both kidney and cardiovascular disease
#Medsky
pubmed.ncbi.nlm.nih.gov/41183334/
#Medsky
pubmed.ncbi.nlm.nih.gov/41183334/
For #flozins I would add this individual-level meta:
1. Hypothesizing: they work across subgroups, in patients with lower UACR, in pts with HF, etc
2. Shows us that we don't completely understand their mechanisms
pubmed.ncbi.nlm.nih.gov/41082889/
1. Hypothesizing: they work across subgroups, in patients with lower UACR, in pts with HF, etc
2. Shows us that we don't completely understand their mechanisms
pubmed.ncbi.nlm.nih.gov/41082889/
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis - PubMed
None.
pubmed.ncbi.nlm.nih.gov
November 24, 2025 at 10:52 PM
For #flozins I would add this individual-level meta:
1. Hypothesizing: they work across subgroups, in patients with lower UACR, in pts with HF, etc
2. Shows us that we don't completely understand their mechanisms
pubmed.ncbi.nlm.nih.gov/41082889/
1. Hypothesizing: they work across subgroups, in patients with lower UACR, in pts with HF, etc
2. Shows us that we don't completely understand their mechanisms
pubmed.ncbi.nlm.nih.gov/41082889/
I'm not sure yet, because I think many similar studies will come: one step closer to GDMT implementation- CONFIDENCE and MIRO-CKD trials #TopNephrology
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinica...
In participants with chronic kidney disease at increased risk of disease progression,
a fixed dose combination of balcinrenone and dapagliflozin was superior to dapagliflozin
alone in reducing albumin...
www.thelancet.com
November 24, 2025 at 9:53 PM
I'm not sure yet, because I think many similar studies will come: one step closer to GDMT implementation- CONFIDENCE and MIRO-CKD trials #TopNephrology
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Also, to mention: the change of perspective in nephrology- aiming for remission, not just slowing CKD 🐌 #TopNephrology
@kidneyint.bsky.social editorial by @brendonneuen.bsky.social and co
www.kidney-international.org/article/S008...
@kidneyint.bsky.social editorial by @brendonneuen.bsky.social and co
www.kidney-international.org/article/S008...
From progression to remission: a new paradigm for success in chronic kidney disease
Recent advances in treatment of chronic kidney disease have changed the clinical paradigm
from slowing inevitable progression to achievable remission. Landmark trials involving
sodium-glucose cotransp...
www.kidney-international.org
November 24, 2025 at 9:48 PM
Also, to mention: the change of perspective in nephrology- aiming for remission, not just slowing CKD 🐌 #TopNephrology
@kidneyint.bsky.social editorial by @brendonneuen.bsky.social and co
www.kidney-international.org/article/S008...
@kidneyint.bsky.social editorial by @brendonneuen.bsky.social and co
www.kidney-international.org/article/S008...
A worthy mention is the Nobel prize winner! #TopNephrology
www.youtube.com/watch?v=vUut...
Peripheral immune tolerance, in our case: how to use it to induce chimerism. #NephJC take on ongoing & finished human kidney transplant studies
www.nephjc.com/news/2025/30...
www.youtube.com/watch?v=vUut...
Peripheral immune tolerance, in our case: how to use it to induce chimerism. #NephJC take on ongoing & finished human kidney transplant studies
www.nephjc.com/news/2025/30...
Announcement of the 2025 Nobel Prize in Physiology or Medicine
YouTube video by Nobel Prize
www.youtube.com
November 24, 2025 at 9:44 PM
A worthy mention is the Nobel prize winner! #TopNephrology
www.youtube.com/watch?v=vUut...
Peripheral immune tolerance, in our case: how to use it to induce chimerism. #NephJC take on ongoing & finished human kidney transplant studies
www.nephjc.com/news/2025/30...
www.youtube.com/watch?v=vUut...
Peripheral immune tolerance, in our case: how to use it to induce chimerism. #NephJC take on ongoing & finished human kidney transplant studies
www.nephjc.com/news/2025/30...
@kdigo.org ADPKD guidelines: because they are the first global guidelines for a genetic kidney-related disease #TopNephrology
www.nephjc.com/news/adpkd-k...
www.nephjc.com/news/adpkd-k...
KDIGO 2025 ADPKD Guidelines Review — NephJC
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, ...
www.nephjc.com
November 24, 2025 at 9:34 PM
@kdigo.org ADPKD guidelines: because they are the first global guidelines for a genetic kidney-related disease #TopNephrology
www.nephjc.com/news/adpkd-k...
www.nephjc.com/news/adpkd-k...
Let's start an atypical-negative study, still practicing changing- ACHIEVE trial #TopNephrology #NephJC
www.nephjc.com/news/achieve
www.nephjc.com/news/achieve
In ESRD is spironolactone an overACHIEVEr? — NephJC
This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?
www.nephjc.com
November 20, 2025 at 10:58 PM
Let's start an atypical-negative study, still practicing changing- ACHIEVE trial #TopNephrology #NephJC
www.nephjc.com/news/achieve
www.nephjc.com/news/achieve
Reposted by Cristina Popa
5/10
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
November 20, 2025 at 12:35 AM
5/10
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!